EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease

Aurore Delvenne iD, Johan Gobom, Suzanne E Schindler, Mara Ten Kate, Lianne M Reus, Valerija Dobricic, Betty M Tijms, Tammie L S Benzinger, Carlos Cruchaga, Charlotte E Teunissen, Inez Ramakers, Pablo Martinez-Lage und 17 weitere

Alzheimer's & Dementia · 2024

DOI: 10.1002/alz.14103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2024. Verfasst von Aurore Delvenne und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Neuropsychology, Alzheimer Centrum Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht…. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomarkers, Neurogranin, Neurofilament Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, ZonMw (Memorabel program), EMIF-AD MBD.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION We aimed to unravel the underlying pathophysiology of the neurodegeneration (N) markers neurogranin (Ng), neurofilament light (NfL), and hippocampal volume (HCV), in Alzheimer's disease (AD) using cerebrospinal fluid (CSF) proteomics. METHODS Individuals without dementia were classified as A+ (CSF amyloid beta [Aβ]42), T+ (CSF phosphorylated tau181), and N+ or N− based on Ng, NfL, or HCV separately. CSF proteomics were generated and compared between groups using analysis of covariance. RESULTS Only a few individuals were A+T+Ng−. A+T+Ng+ and A+T+NfL+ showed different proteomic profiles compared to A+T+Ng− and A+T+NfL−, respectively. Both Ng+ and NfL+ were associated with neuroplasticity, though in opposite directions. Compared to A+T+HCV−, A+T+HCV+ showed few proteomic changes, associated with oxidative stress. DISCUSSION Different N markers are associated with distinct neurodegenerative processes and should not be equated. N markers may differentially complement disease staging beyond amyloid and tau. Our findings suggest that Ng may not be an optimal N marker, given its low incongruency with tau pathophysiology. Highlights In Alzheimer's disease, neurogranin (Ng)+, neurofilament light (NfL)+, and hippocampal volume (HCV)+ showed differential protein expression in cerebrospinal fluid. Ng+ and NfL+ were associated with neuroplasticity, although in opposite directions. HCV+ showed few proteomic changes, related to oxidative stress. Neurodegeneration (N) markers may differentially refine disease staging beyond amyloid and tau. Ng might not be an optimal N marker, as it relates more closely to tau.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseBiomarkersNeurograninNeurofilament Proteinstau ProteinsProteomicsHippocampusAmyloid beta-PeptidesHumansFemaleMaleAgedMiddle AgedPeptide Fragments

Stichwörter der Autor:innen

Alzheimer's diseasebiomarkerscerebrospinal fluidhippocampal volumeneurodegeneration markersneurofilament lightneurograninpathophysiologyproteomics

Substanzen

BiomarkersNeurograninNeurofilament Proteinstau Proteinsneurofilament protein LAmyloid beta-PeptidesPeptide Fragmentsamyloid beta-protein (1-42)

Autor:innen und Institutionen

  • Department of Psychiatry and Neuropsychology, Alzheimer Centrum Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.
  • Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
  • Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.

ORCID-Profile: Aurore Delvenne

Förderung

  • NIA NIH HHS
  • ZonMw (Memorabel program)
  • EMIF-AD MBD
  • anonymous foundation

Zitieren

APA

Delvenne, A., Gobom, J., Schindler, S. E., Kate, M. T., Reus, L. M., Dobricic, V., Tijms, B. M., Benzinger, T. L. S., Cruchaga, C., Teunissen, C. E., Ramakers, I., Martinez-Lage, P., Tainta, M., Vandenberghe, R., Schaeverbeke, J., Engelborghs, S., Roeck, E., Popp, J., Peyratout, G., …, & Vos, S. J. B. (2024). CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14103

Vancouver

Delvenne A, Gobom J, Schindler SE, Kate MT, Reus LM, Dobricic V, et al. CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease. Alzheimer's & Dementia. 2024. doi:10.1002/alz.14103

BibTeX
@article{Delvenne2024,
  author = {Delvenne, Aurore and Gobom, Johan and Schindler, Suzanne E and Kate, Mara Ten and Reus, Lianne M and Dobricic, Valerija and Tijms, Betty M and Benzinger, Tammie L S and Cruchaga, Carlos and Teunissen, Charlotte E and Ramakers, Inez and Martinez-Lage, Pablo and Tainta, Mikel and Vandenberghe, Rik and Schaeverbeke, Jolien and Engelborghs, Sebastiaan and Roeck, Ellen De and Popp, Julius and Peyratout, Gwendoline and Tsolaki, Magda and Freund-Levi, Yvonne and Lovestone, Simon and Streffer, Johannes and Barkhof, Frederik and Bertram, Lars and Blennow, Kaj and Zetterberg, Henrik and Visser, Pieter Jelle and Vos, Stephanie J B},
  title = {CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2024},
  doi = {10.1002/alz.14103}
}
Kostenlos starten →